Revenue: As of FY2025 Q2, the actual value is USD 9.03 M.

EPS: As of FY2025 Q2, the actual value is USD -0.57.

EBIT: As of FY2025 Q2, the actual value is USD -5.166 M.

Segment Revenue

• Total revenues for the second quarter of 2025 were $9.0 million, a 15% increase from the same period of the prior year.
• For the first six months of 2025, revenue was $17.7 million, a 12% increase from the comparable period in 2024.

Operational Metrics

• Total operating expenses were $14.1 million for the second quarter of 2025 compared with $12.9 million for the second quarter of 2024.
• Selling, general and administrative expenses were $10.5 million for the second quarter of 2025 compared with $7.9 million for the second quarter of 2024.
• The net loss for the second quarter of 2025 was $5.3 million, compared with a net loss of $0.3 million for the prior-year quarter.
• Adjusted EBITDA for the second quarter of 2025 was - $5.1 million compared with - $4.7 million for the second quarter of 2024.

Cash Flow

• Cash and cash equivalents were $7.2 million as of June 30, 2025, compared with $5.9 million at December 31, 2024.

Unique Metrics

• Agreed to major restructuring of relationship with Biofrontera AG, including acquisition of United States Intellectual Property (IP) and New Drug Applications (NDA) and control of manufacturing, supported by an additional $11 million in funding for the company.

Outlook / Guidance

• The company has changed its approach in 2025 by transforming customer segmentation and focusing strategy, which led to increased sales volume and higher revenues. The restructuring agreement with Biofrontera AG is expected to result in cost savings and improved trial efficiency. The $11 million investment and improvements in promotional strategy and sales effectiveness have positioned the company strongly for the rest of the year and beyond.